🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Join Vivien Knospe from FUJIFILM WAKO Chemicals to discuss the Monocyte Activation Test (MAT)! Learn about: ✅ MAT implementation in the EU ✅ Status in pharmacopoeias (USP, EP, JP, ChP) ✅ Performing a MAT assay 📅 Register now: bit.ly/4ePw57C

The drug candidate included in the AbbVie deal transports the antibody across the blood-brain barrier to enable degradation of amyloid beta plaque. #Alzheimers europeanpharmaceuticalreview.com/news/235282/ab…

A key benefit of the film bag “is its simplicity because no equipment for mechanical aeration is required”. #microbiology #EPRTalks europeanpharmaceuticalreview.com/news/235696/in…

🚨 Last Chance! 🚨 Join us this week for a webinar with Vivien Knospe from FUJIFILM WAKO Chemicals on the Monocyte Activation Test (MAT)! 📅 Register now: bit.ly/4ePw57C #mat #monocyteactivationtest #webinar

As part of the acquisition, BioNTech SE will gain rights to a state-of-the-art biologics manufacturing facility. europeanpharmaceuticalreview.com/news/236460/bi… #biologics #EPRTalks

Investment in Sanofi's Lyon Gerland site will aid internal bioproduction of a type 1 #diabetes drug, enabling market availability in 2027. europeanpharmaceuticalreview.com/news/237061/sa… #pharmaceuticalmanfacturing #EPRTalks

The new appointments by Amgen 🧪🔬🧬 and Pfizer Inc. will drive development of new medicines across numerous therapeutic areas such as rare disease and cancer. europeanpharmaceuticalreview.com/news/237695/am… #EPRTalks

AD | Making spirits bright! Save 25% and enjoy free gummi bears with our most popular nucleic purification kits. Whether you’re looking for #DNA, #RNA, or #plasmidpurification, clean-up for #NGS, gels, or PCR, we’ve got the perfect kit. bit.ly/4fVrYrC

“By combining our expertise in #clinicaltrials and #lifesciences with world-class researchers, we can accelerate the development of groundbreaking treatments that will benefit patients across [the UK and Switzerland]” says UK Health Minister. #EPRTalks europeanpharmaceuticalreview.com/news/239768/16…

"These reforms protect the safe development of pioneering new treatments," Dr June Raine, MHRAgovuk Chief Executive stated. #EPRTalks europeanpharmaceuticalreview.com/news/240039/le…

"Approval by the [European Commission] is significant because Elahere is the first new medication approved specifically for platinum-resistant ovarian cancer since 2014". #pharma #EPRTalks europeanpharmaceuticalreview.com/article/240018…

As part of the agreement, Bristol Myers Squibb is responsible for development and commercialisation of the novel antibodies and related products. #biologics #EPRtalks europeanpharmaceuticalreview.com/news/240639/br…

Gene editing technologies are expected to innovate #pharma personalised medicine in 2025, says Clarivate for Life Sciences & Healthcare 's latest Drugs to Watch report. #drugdevelopment europeanpharmaceuticalreview.com/article/242863…

The acquisition will include rights to a TKI molecule, which according to GSK's CSO, has potential to help close a major gap in the current standard of care of gastrointestinal stromal tumours. europeanpharmaceuticalreview.com/news/243346/gs…

The new recommendations will support health technology assessment (HTA) and aid technology developers to provide data for evidence submissions. europeanpharmaceuticalreview.com/news/244505/ne…

Oncology continues to be the dominant area in early-phase ATMP clinical trials for investigational therapies, the report data shows. #pharma #clinicaltrials europeanpharmaceuticalreview.com/news/244782/ea…

"With nearly two-thirds of all major #pharma company revenues set to come from dealmaking in the next five years, deals will remain at the centre of #lifesciences strategy," says EY Global Life Sciences Deals Leader. europeanpharmaceuticalreview.com/article/245077…

"This year’s figures demonstrate that biotech is a vibrant growth sector of the UK economy with an exceptional ability to attract global investment," says BioIndustry Association (BIA)'s CEO. europeanpharmaceuticalreview.com/news/245461/uk…

“Excitingly, advances in gene editing are happening very rapidly... it seems likely that cheaper, safer and more effective forms of gene editing will emerge for sickle cell disease over the coming years,” commented Professor Rees of King’s College London. europeanpharmaceuticalreview.com/news/245870/ni…

According to analysis by Moderna, 20 percent of participants in UK industry-sponsored clinical research were enrolled in a Moderna trial in 2023/2024. europeanpharmaceuticalreview.com/news/246638/mo…